- Home
- IMMX vs GMTL Comparison
IMMX vs GMTL Comparison
Compare IMMX & GMTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMX | GMTL |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.1M | 626.4M |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | IMMX | GMTL |
|---|---|---|
| Price | $10.22 | $9.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $19.20 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 2.3M | 204.2K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.94 | $8.60 |
| 52 Week High | $12.14 | $22.21 |
Technical Indicators
Market Signals| Indicator | IMMX | GMTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 28.46 |
| Support Level | $7.99 | N/A |
| Resistance Level | $10.61 | $17.88 |
| Average True Range (ATR) | 0.87 | 1.12 |
| MACD | -0.09 | -0.39 |
| Stochastic Oscillator | 22.83 | 16.70 |
Price Performance
Historical ComparisonAbout IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About GMTL Guardian Metal Resources PLC ADS
Guardian Metal Resources PLC focuses on metals exploration and development, with a focus on precious metals exploration in North America. The Company has one business segment, which is the exploration and evaluation of mineral resources in Nevada, USA. Its exploration projects comprise the Pilot Mountain Project, Tempiute Project, Golconda Summit Project, Stonewall Project, and Garfield Project, and the Group is the operator of the Golconda Summit Project.